• For Patients
logo
  • COVID-19 Resources
  • How Zephyr Valves Work
  • Benefits & Risks
  • Patient Selection
  • Patient Stories
  • Make a Referral
  • Search
  • For Patients

Minimally-invasive Treatment Option

PULMONX NAMES INDUSTRY VETERAN TO BOARD OF DIRECTORS

Pulmonx Names Industry Veteran to Board of Directors Redwood City,…


by pulmonxprod

PULMONX ANNOUNCES THAT UNITEDHEALTHCARE, THE LARGEST COMMERCIAL INSURER IN THE UNITED STATES, HAS LIFTED COVERAGE RESTRICTIONS ON THE ZEPHYR VALVE, A MINIMALLY-INVASIVE TREATMENT OPTION FOR SEVERE EMPHYSEMA (COPD)

Both UnitedHealthcare® and EmblemHealth recently announced positive coverage…


by pulmonxprod

THE NEW 2020 REPORT FROM THE GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE (GOLD) GIVES HIGHEST EVIDENCE RATING TO ENDOBRONCHIAL VALVES, INCLUDING THE ZEPHYR VALVE, FOR TREATMENT OF EMPHYSEMA / COPD

GOLD’s evidence “A” rating affirms that endobronchial valves, like the Zephyr…


by pulmonxprod

© 2018-Present Pulmonx Corporation or its affiliates.  All rights reserved. All trademarks are property of their respective owners.  |  Site Designed by The Deciding Factor, Inc.

D0838EN_A August 2019  |  Privacy Policy  |  Terms of Use  |  Sitemap  |  Prescriptive Information  |  In the News  |  Contact Us

  • Make a Referral

  • Request Materials

Privacy Preference Center

Privacy Preferences